Dupilumab, a monoclonal antibody that inhibits both interleukin (IL)-4 and IL-13 signaling, is an effective treatment option in moderate-to-severe atopic dermatitis (AD). Patients with AD are already at increased risk of developing conjunctivitis, and clinical trials and case reports have shown a greater incidence of conjunctivitis in individuals with AD treated with dupilumab. As this is one of the more commonly reported side effects of this biologic agent, it is important that clinicians are aware of this association and advise patients receiving dupilumab to report signs of conjunctivitis. This review summarizes the risk factors, clinical features, and management options for patients with AD presenting with conjunctivitis after receiving dupilumab therapy.

中文翻译：

---

Dupilumab 相关性结膜炎的识别和管理临床医生指南。

Dupilumab 是一种抑制白细胞介素 (IL)-4 和 IL-13 信号传导的单克隆抗体，是中度至重度特应性皮炎 (AD) 的有效治疗选择。AD 患者发生结膜炎的风险已经增加，临床试验和病例报告显示，在接受 dupilumab 治疗的 AD 患者中，结膜炎的发生率更高。由于这是这种生物制剂最常报告的副作用之一，临床医生必须意识到这种关联并建议接受 dupilumab 的患者报告结膜炎体征。本综述总结了接受 dupilumab 治疗后出现结膜炎的 AD 患者的危险因素、临床特征和管理选择。